Evidence map›Paper›PMID 25837018›Full record

ArticleHeart, lung & circulation2015

Differential Effects of Prevention and Reversal Treatment with Lisinopril on Left Ventricular Remodelling in a Rat Model of Heart Failure.

Gregory L Brower, Scott P Levick, Joseph S Janicki

Open access · greenAbstract read
In one paragraph

Article in Heart, lung & circulation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Gregory L BrowerCell Biology and Anatomy, School of Medicine, University of South Carolina, Columbia, SC 29208, USA.
Scott P LevickPharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI 53226, USA; Cardiovascular Center, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Joseph S JanickiCell Biology and Anatomy, School of Medicine, University of South Carolina, Columbia, SC 29208, USA. Electronic address: Joseph.Janicki@uscmed.sc.edu.
University of South Carolina · USMedical College of Wisconsin · US

Funding

CARDIAC MAST CELL--ROLE IN PATHOGENESIS OF HEART FAILURER01HL062228 · NHLBI · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI JANICKI, JOSEPH S · 1999 to 2007
$2.8M
Sexual hormones, cardiac mast cells and cardioprotectionR01HL073990 · NHLBI · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI JANICKI, JOSEPH S · 2004 to 2007
$1.5M
NHLBI NIH HHS R01 HL062228NHLBI NIH HHS R01 HL073990NHLBI NIH HHS R01-HL-073990NHLBI NIH HHS R01-HL-62228
6 · The paper itself

Abstract

backgroundAngiotensin converting enzyme (ACE) inhibitors such as lisinopril, represent the front line pharmacological treatment for heart failure, which is characterised by marked left ventricular (LV) dilatation and hypertrophy. This study sought to determine whether initiating treatment with ACE inhibitors at different stages in the remodelling process would alter the efficacy of treatment.

methodsTo this end, LV size and function were determined in the aortocaval (AV) fistula model of volume overload-induced heart failure. Sprague-Dawley rats were assigned to sham, untreated AV fistula (21 weeks), AV fistula treated with lisinopril (21 weeks), or AV fistula treated with lisinopril from six to 21 weeks post-fistula groups.

resultsAdministration of lisinopril for the entire 21-week period prevented LV dilatation, attenuated myocardial hypertrophy and prevented changes in myocardial compliance and contractility, whereas delaying initiation of treatment until six weeks post-fistula attenuated LV dilatation and hypertrophy, however, the delayed onset of treatment had no beneficial effect on ventricular compliance or systolic function.

conclusionsThe results demonstrate differential effects that can occur with ACE inhibitors depending on the stage during the remodelling process at which treatment is administered.

Indexed as

CardiomegalyHeart FailureAnimalsDisease Models, AnimalLisinoprilMaleMyocardial ContractionRatsRats, Sprague-DawleyVentricular RemodelingLisinoprilAngiotensin converting enzyme inhibitorHeart failureHypertrophyVolume overload

Identifiers

PMID25837018
PMCPMC4564313
OpenAlexW1997122776

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.